Search clinical trials for: Open Label Extension

Total 10920 results

Biogen

Completed

Open-Label Natalizumab Safety Extension Study

Multiple Sclerosis

United States
Biogen

Completed

Open-Label Safety Extension Study of Avonex

Multiple Sclerosis
Ambrilia Biopharma, Inc.

Completed

Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

Acromegaly

Belarus, Hungary, Serbia, Ukraine, Romania, Slovakia
Endo Pharmaceuticals

Completed

Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

Lower Back Pain | Cancers, Pain

United States
AstraZeneca

Completed

Open-Label Extension of Other SZ1839 (Iressa) Trials

Cancer
Solvay Pharmaceuticals

Completed

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Early Stage Parkinson's Disease

United States, Australia, Czech Republic, Estonia, Germany, India, Italy, Lithuania, Malaysia, Netherlands, Poland, Portugal, South Africa, Taiwan, Thailand
Solvay Pharmaceuticals

Completed

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

Early Stage Parkinson's Disease

United States, Argentina, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Finland, India, Israel, Mexico, New Zealand, Peru, Romania, Russian Federation, Serbia, Slovakia, South Africa, Sweden, Ukraine
Pfizer

Completed

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome

Overactive Bladder Syndrome

United States
Pfizer

Completed

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome

Overactive Bladder Syndrome

Germany
Radboud University Medical Center
Ipsen

Unknown

Open-Label Extension of LOCKCYST Trial (LOCKCYST-ext)

Liver Diseases | Hepatomegaly | Polycystic Liver Disease | Polycystic Kidney | Autosomal Dominant

Netherlands, Belgium
Pfizer

Completed

Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase

Overactive Bladder

United States
Provident Clinical Research
Reliant Pharmaceuticals

Unknown

An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin

Mixed Dyslipidemia
Astellas Pharma Inc

Completed

Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Keratoconjunctivitis | Conjunctivitis

Japan
Daiichi Sankyo, Inc.

Completed

Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes

Type 2 Diabetes

United States, Peru, Mexico
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Open Label Extension Study of Bifeprunox

Schizophrenia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis

Ankylosing Spondylitis
Abbott

Completed

A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.

Migraines

United States
Bellus Health Inc

Unknown

Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
H. Lundbeck A/S

Completed

A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia

Primary Insomnia

Germany
Eli Lilly and Company

Completed

Open-Label Duloxetine Extension Phase in Patients Who Have Completed Previous Duloxetine Trials

Major Depressive Disorder

Spain
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis

Ankylosing Spondylitis

Belgium
Pfizer

Completed

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

Epilepsies, Partial | Epilepsy, Complex Partial

Spain, France, Canada, Germany, Italy, Lithuania, Austria, United Kingdom
NeurogesX

Terminated

An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain

HIV Infections | Pain | Diabetes Mellitus | Diabetic Neuropathies | Peripheral Nervous System Diseases | Neuralgia | Herpes Zoster | Polyneuropathies
Wave Life Sciences Ltd.

Not yet recruiting

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD (RestorAATion-2)

Alpha-1 Antitrypsin Deficiency
Nutrition & Sante Iberia
Adknoma Health Research

Recruiting

Open-labelled Study to Evaluate the Effect of SE5-OH Tablets on Healthy Women With Menopausal Symptoms

Menopause

Spain
Sunnybrook Health Sciences Centre

Recruiting

Accelerated, Theta-burst Stimulation for the Treatment of Post-concussion Syndrome - Open-label Pilot Study

Post-Concussion Syndrome

Canada
Ferring Pharmaceuticals

Not yet recruiting

A Phase 4, Multi-center, Open Label Trial to Evaluate Efficacy of Retreatment With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose (ABLE-42)

Bladder Cancer | CIS | Ta/T1
Vertex Pharmaceuticals Incorporated

Not yet recruiting

A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults

Pain
Lund University Hospital

Not yet recruiting

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) (PERELI)

Dedifferentiated Liposarcoma

Sweden, Norway
GlaxoSmithKline

Not yet recruiting

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

Asthma

United States, Argentina, Japan, Taiwan, Canada, Korea, Republic of, Australia
M.D. Anderson Cancer Center

Not yet recruiting

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
University of California, San Francisco

Not yet recruiting

Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis

Adolescent Idiopathic Scoliosis (AIS)

United States
Qiong Fu

Not yet recruiting

A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Italy, Spain, Poland, Canada, Korea, Republic of, Hungary, Turkey, Taiwan, United Kingdom, Japan, Austria, Australia, Germany, Brazil
Institute of Mental Health, Singapore

Recruiting

An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms (NOBLE-TMS)

Schizophrenia; Negative Type

Singapore
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (ALBUCHIP)

Postoperative Complications | Peritoneal Neoplasms | Fluid Therapy | Hyperthermic Intraperitoneal Chemotherapy | Intraoperative Care
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

China, Taiwan, Korea, Republic of, Australia
Cosima Locher
Brown University; University of Basel

Not yet recruiting

Conditioned Open-label Placebos to Facilitate Opioid Reduction in Patients With Chronic Non-cancer Pain (ROM)

Chronic Non-cancer Pain
Dosentrx Ltd.

Not yet recruiting

Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform

Any Solid Oral Medication

United States
Fondation Ophtalmologique Adolphe de Rothschild

Not yet recruiting

Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial. (IMCOMG)

Ocular Myasthenia Gravis
Nanjing First Hospital, Nanjing Medical University

Not yet recruiting

Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study

Helicobacter Pylori Infection | Tegoprazan | Furazolidone
Caporali Elena
Cardiocentro Ticino

Recruiting

Correct Mobilization Time After CIED Implantation: A Single-centre, Open-label, Non-inferiority RCT

Defibrillators, Implantable | Pacemaker

Switzerland
Sir Ganga Ram Hospital

Recruiting

Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis: An Open Label Pilot Study

Hepatic Encephalopathy

India
Cabaletta Bio

Not yet recruiting

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Systemic Sclerosis | Scleroderma

United States
M.D. Anderson Cancer Center
Active Biotech AB

Not yet recruiting

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-Essential Thrombocytosis Myelofibrosis

United States
Johns Hopkins University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Not yet recruiting

CAPABLE Transplant

Depression | Quality of Life | End Stage Renal Disease | Disability Physical

United States
Lindsey Russell, MD
Napo Pharmaceuticals, Inc.

Not yet recruiting

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

Short Bowel Syndrome

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Schizophrenia, Schizoaffective Disorder

United States
M.D. Anderson Cancer Center

Not yet recruiting

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Triple Negative Breast Cancer | Stage 1 cT1b-T1cN0M0

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

Schizophrenia

United States

3

Subscribe